IGF-1R Antibody-Drug Conjugate for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IGF-1R expressing cancers are hindered by ineffective diagnostic antibodies leading to false positives and negatives, and the failure of anti-IGF-1R antibodies in clinical trials due to inappropriate patient selection and the challenge of targeting IGF-1R, which is widely expressed in normal cells.
Innovation Solution
A method involving the use of a first IGF-1R antibody for determining the IGF-1R status of a subject, followed by treatment with an antibody-drug-conjugate (ADC) comprising a second IGF-1R antibody that binds to IGF-1R and is internalized, delivering a drug moiety to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a first IGF-1R antibody is used for determining the IGF-1R status of a cancer, then the diagnostic accuracy is improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The treatment protocol is segmented into two distinct phases: a diagnostic phase using a first IGF-1R antibody to determine cancer status, and a therapeutic phase using an ADC comprising a second IGF-1R antibody. This segmentation allows each antibody to be optimized for its specific function while maintaining overall protocol manageability through clear stage separation.
2Reliability
If an antibody-drug-conjugate is used for treatment, then the therapeutic effectiveness is improved, but the risk of affecting normal cells increases
Solution Approach 1:
The ADC is designed with localized functionality: the antibody component provides cancer-specific targeting through IGF-1R binding, while the drug moiety provides cytotoxic activity. This local quality differentiation ensures that the harmful drug effect is concentrated only at the tumor site where IGF-1R is overexpressed, minimizing impact on normal cells that do not express the target antigen.
Solution Approach 2:
The antibody component acts as an intermediary that selectively delivers the drug moiety to cancer cells expressing IGF-1R. This intermediary function ensures that the cytotoxic drug is transported specifically to the tumor site through antigen-antibody binding, preventing systemic distribution and reducing off-target effects on normal cells.
3Reliability
If patient selection is based on accurate IGF-1R status determination, then the treatment success rate is improved, but the time required for patient evaluation increases
Solution Approach 1:
IGF-1R status determination is performed as a preliminary action before initiating ADC treatment. By establishing the diagnostic criterion in advance and using well-defined antibody binding assays, the evaluation process is streamlined and can be completed efficiently, allowing timely identification of suitable patients without delaying treatment initiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted and effective treatment of IGF-1R expressing cancers by ensuring accurate patient selection and minimizing impact on normal cells through specific internalization of the ADC, potentially overcoming previous treatment failures.
Implementation Method 1
a first IGF-1R antibody being: i) an antibody, or any antigen binding fragment thereof, comprising a heavy chain with CDR-H1 of SEQ ID No. 1, CDR-H2 of SEQ ID No. 2, and CDR-H3 of SEQ ID No. 3
Implementation Method 2
Ab is a second IGF-1R antibody, or an antigen binding fragment thereof, which binds to the human IGF-1R and which is internalized following its binding to IGF-1R
Implementation Method 3
which is internalized following its binding to IGF-1R
Implementation Method 4
delivering a drug moiety to cancer cells
Implementation Method 5
treating a subject in need thereof with an IGF-1R targeting therapy
Data Source
AI summary
The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.